Last reviewed · How we verify
Naltrexone-Bupropion Combination
At a glance
| Generic name | Naltrexone-Bupropion Combination |
|---|---|
| Also known as | Contrave, Mysimba |
| Sponsor | Columbia University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Pharmacological and Behavioral Treatment After Bariatric Surgery: Acute (Stage 1) (PHASE2, PHASE3)
- A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients (PHASE1, PHASE2)
- Development of a MHBC Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Patients (PHASE1)
- Individualized Pharmacological Approach to Obesity in Patients With Bipolar Disorder (PHASE4)
- Pharmacological and Behavioral Treatments After Bariatric Surgery: Maintenance Treatment (Stage 2a) (PHASE2, PHASE3)
- A Research Study Comparing Wegovy to Other Weight Management Drugs in People Living With Obesity in America (PHASE4)
- Cognitive-Behavioral and Pharmacologic (LDX) Treatment of Binge-Eating Disorder and Obesity: Medication Change for Non-Responders (PHASE2, PHASE3)
- Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Naltrexone-Bupropion Combination CI brief — competitive landscape report
- Naltrexone-Bupropion Combination updates RSS · CI watch RSS
- Columbia University portfolio CI